PF-06840003   Click here for help

GtoPdb Ligand ID: 9565

Synonyms: EOS200271 | PF06840003
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: PF-06840003 is a small molecule IDO1 inhibitor, designed as a cancer immunotherapeutic. It is claimed as compound 1 in patent WO2015173764 [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 1
Topological polar surface area 61.96
Molecular weight 232.06
XLogP 0.79
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES Fc1cc2c(C3CC(=O)NC3=O)c[nH]c2cc1
Isomeric SMILES Fc1cc2c(C3CC(=O)NC3=O)c[nH]c2cc1
InChI InChI=1S/C12H9FN2O2/c13-6-1-2-10-7(3-6)9(5-14-10)8-4-11(16)15-12(8)17/h1-3,5,8,14H,4H2,(H,15,16,17)
InChI Key MXKLDYKORJEOPR-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
The first in patient trial of PF-06840003 is evaluating its effect in subjects with malignant gliomas (see NCT02764151, Phase 1).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
IDO1 is an immunosuppressive enzyme that is induced in a wide range of cancers. Inhibiting IDO1 helps restore immune surveillance of tumors, and it is hoped that this will effect tumor destruction/elimination.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02764151 First in Patient Study for PF-06840003 in Malignant Gliomas Phase 1 Interventional Pfizer